{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:04:32Z","timestamp":1782176672640,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03081-8","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:00:48Z","timestamp":1734512448000},"page":"1044-1060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"42","author":[{"given":"Marla","family":"Dubinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-5370","authenticated-orcid":false,"given":"Aisha","family":"Vadhariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Clucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Stassek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane K.","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"1","key":"3081_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2020.18936","volume":"325","author":"K Cushing","year":"2021","unstructured":"Cushing K, Higgins PDR. Management of Crohn disease: a review. JAMA. 2021;325(1):69\u201380.","journal-title":"JAMA"},{"issue":"10432","key":"3081_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403(10432):1177\u201391.","journal-title":"Lancet"},{"issue":"5","key":"3081_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"5","key":"3081_CR4","first-page":"233","volume":"17","author":"JF Colombel","year":"2021","unstructured":"Colombel JF. Disease clearance in inflammatory bowel disease. Gastroenterol Hepatol. 2021;17(5):233\u20135.","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"3081_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.crohns.2013.04.007","volume":"8","author":"M van der Have","year":"2014","unstructured":"van der Have M, van der Aalst KS, Kaptein AA, Leenders M, Siersema PD, Oldenburg B, Fidder HH. Determinants of health-related quality of life in Crohn\u2019s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8(2):93\u2013106.","journal-title":"J Crohns Colitis"},{"issue":"41","key":"3081_CR6","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.3748\/wjg.v29.i41.5668","volume":"29","author":"AG Gravina","year":"2023","unstructured":"Gravina AG, Pellegrino R, Durante T, Palladino G, D\u2019Onofrio R, Mammone S, et al. Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: The \u201cBE-FIT-IBD\u201d study. World J Gastroenterol. 2023;29(41):5668\u201382.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3081_CR7","doi-asserted-by":"publisher","first-page":"otad052","DOI":"10.1093\/crocol\/otad052","volume":"5","author":"C Ha","year":"2023","unstructured":"Ha C, Naegeli AN, Lukanova R, Shan M, Wild R, Hennessy F, et al. Rectal urgency among patients with ulcerative colitis or Crohn\u2019s disease: analyses from a global survey. Crohns Colitis 360. 2023;5(4):otad052.","journal-title":"Crohns Colitis 360"},{"issue":"11","key":"3081_CR8","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.14309\/ajg.0000000000002404","volume":"118","author":"M Dubinsky","year":"2023","unstructured":"Dubinsky M, Bleakman AP, Panaccione R, Hibi T, Schreiber S, Rubin D, et al. Bowel urgency in ulcerative colitis: current perspectives and future directions. Am J Gastroenterol. 2023;118(11):1940\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3081_CR9","first-page":"95","volume":"19","author":"J Pakpoor","year":"2023","unstructured":"Pakpoor J, Travis S. Why studying urgency is urgent. Gastroenterol Hepatol. 2023;19(2):95\u2013100.","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"3081_CR10","doi-asserted-by":"publisher","first-page":"otab046","DOI":"10.1093\/crocol\/otab046","volume":"3","author":"GK Dawwas","year":"2021","unstructured":"Dawwas GK, Jajeh H, Shan M, Naegeli AN, Hunter T, Lewis JD. Prevalence and factors associated with fecal urgency among patients with ulcerative colitis and Crohn\u2019s disease in the study of a prospective adult research cohort with inflammatory bowel disease. Crohns Colitis 360. 2021;3(3):otab046.","journal-title":"Crohns Colitis 360"},{"issue":"6","key":"3081_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649\u201370.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3081_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3081_CR13","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s10620-024-08434-5","volume":"69","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, Hunter Gibble T, Panaccione R, Rubin DT, Travis S, Hibi T, et al. Patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe Crohn\u2019s disease in US and Europe: results from the cross-sectional CONFIDE study. Dig Dis Sci. 2024;69(7):2333\u201344.","journal-title":"Dig Dis Sci"},{"key":"3081_CR14","doi-asserted-by":"publisher","first-page":"izae044","DOI":"10.1093\/ibd\/izae044","volume":"30","author":"V Jairath","year":"2024","unstructured":"Jairath V, Hunter Gibble T, Potts Bleakman A, Chatterton K, Medrano P, McLafferty M, et al. Patient perspectives of bowel urgency and bowel urgency-related accidents in ulcerative colitis and Crohn\u2019s disease. Inflamm Bowel Dis. 2024;30:izae044.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"3081_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","volume":"49","author":"F Casellas","year":"2017","unstructured":"Casellas F, Herrera-de Guise C, Robles V, Navarro E, Borruel N. Patient preferences for inflammatory bowel disease treatment objectives. Dig Liver Dis. 2017;49(2):152\u20136.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"3081_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","volume":"13","author":"E Louis","year":"2020","unstructured":"Louis E, Ramos-Goni JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, et al. A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient. 2020;13(3):317\u201325.","journal-title":"Patient"},{"issue":"3","key":"3081_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","volume":"17","author":"E Schoefs","year":"2023","unstructured":"Schoefs E, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L, et al. What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study. J Crohns Colitis. 2023;17(3):379\u201388.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"3081_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113(4):481\u2013517.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3081_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s Disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"3081_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ibd\/izad142","volume":"30","author":"S Travis","year":"2024","unstructured":"Travis S, Potts Bleakman A, Dubinsky MC, Schreiber S, Panaccione R, Hibi T, et al. The communicating needs and features of IBD experiences (CONFIDE) Study: US and European patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2024;30(6):939\u201349.","journal-title":"Inflamm Bowel Dis"},{"key":"3081_CR21","unstructured":"US Food and Drug Administration: Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, food and drug administration staff, and other stakeholders; 2020. https:\/\/www.fda.gov\/media\/139088\/download. Accessed Oct 2024"},{"issue":"1","key":"3081_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, et al. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes. 2022;6(1):31.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"3081_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Shan M, Delbecque L, Lissoos T, Hunter T, Harding G, et al. Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis. J Patient Rep Outcomes. 2022;6(1):114.","journal-title":"J Patient Rep Outcomes"},{"issue":"12","key":"3081_CR24","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1007\/s11136-023-03494-y","volume":"32","author":"MC Dubinsky","year":"2023","unstructured":"Dubinsky MC, Delbecque L, Hunter T, Harding G, Stassek L, Moses RE, Lewis JD. Validation of the bowel urgency numeric rating scale in patients with Crohn\u2019s disease: results from a mixed methods study. Qual Life Res. 2023;32(12):3403\u201315.","journal-title":"Qual Life Res"},{"key":"3081_CR25","unstructured":"US Food and Drug Administration: Patient-focused drug development: Incorporating clinical outcome assessments into endpoints for regulatory decision-making. Guidance for industry, food and drug administration staff, and other stakeholders; 2023. https:\/\/www.fda.gov\/media\/166830\/download. Accessed Oct 2024"},{"issue":"3","key":"3081_CR26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","volume":"96","author":"G Guyatt","year":"1989","unstructured":"Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96(3):804\u201310.","journal-title":"Gastroenterology"},{"issue":"4","key":"3081_CR27","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","volume":"14","author":"EJ Irvine","year":"2008","unstructured":"Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14(4):554\u201365.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"3081_CR28","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol. 1996;91(8):1571\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3081_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn\u2019s disease activity index. Gastroenterology. 1976;70(3):439\u201344.","journal-title":"Gastroenterology"},{"issue":"10066","key":"3081_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375.","journal-title":"Lancet"},{"issue":"9","key":"3081_CR31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/apt.16805","volume":"55","author":"ECL Wong","year":"2022","unstructured":"Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn\u2019s disease. Aliment Pharmacol Ther. 2022;55(9):1151\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3081_CR32","first-page":"CD012878","volume":"2019","author":"M Abbass","year":"2019","unstructured":"Abbass M, Cepek J, Parker CE, Nguyen TM, MacDonald JK, Feagan BG, et al. Adalimumab for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2019;2019(11):CD012878.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3081_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12876-022-02347-1","volume":"22","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol. 2022;22(1):291.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"3081_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505\u201312.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"3081_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30\u201346.","journal-title":"Psychol Methods"},{"issue":"2","key":"3081_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420\u20138.","journal-title":"Psychol Bull"},{"key":"3081_CR37","volume-title":"Applied statistics for the behavioral sciences","author":"DE Hinkle","year":"2003","unstructured":"Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5th ed. Boston: Houghton Mifflin; 2003.","edition":"5"},{"key":"3081_CR38","volume-title":"The analysis of variance","author":"H Scheff\u00e9","year":"1959","unstructured":"Scheff\u00e9 H. The analysis of variance. Hoboken: Wiley; 1959."},{"issue":"2","key":"3081_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/gast.2002.31072","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease. Gastroenterology. 2002;122(2):512\u201330.","journal-title":"Gastroenterology"},{"issue":"3","key":"3081_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","volume":"10","author":"D Farrell","year":"2016","unstructured":"Farrell D, McCarthy G, Savage E. Self-reported symptom burden in individuals with inflammatory bowel disease. J Crohns Colitis. 2016;10(3):315\u201322.","journal-title":"J Crohns Colitis"},{"key":"3081_CR41","unstructured":"National Library of Medicine: NCT03926130. A study of mirikizumab (LY3074828) in participants with Crohn\u2019s disease (VIVID-1); 2023. https:\/\/www.clinicaltrials.gov\/study\/NCT03926130. Accessed Oct 2024"},{"key":"3081_CR42","doi-asserted-by":"publisher","first-page":"1404880","DOI":"10.3389\/fmed.2024.1404880","volume":"11","author":"J Wu","year":"2024","unstructured":"Wu J, Fang Y, Bai B, Wu Y, Liu Q, Hu J, et al. Clinical characteristics and the risk factors for the exacerbation of symptoms in patients with inflammatory bowel disease during the COVID-19 pandemic. Front Med. 2024;11:1404880.","journal-title":"Front Med"},{"issue":"10","key":"3081_CR43","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.dld.2022.07.016","volume":"54","author":"R Pellegrino","year":"2022","unstructured":"Pellegrino R, Pellino G, Selvaggi F, Federico A, Romano M, Gravina AG. Therapeutic adherence recorded in the outpatient follow-up of inflammatory bowel diseases in a referral center: damages of COVID-19. Dig Liver Dis. 2022;54(10):1449\u201351.","journal-title":"Dig Liver Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03081-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:52:12Z","timestamp":1738407132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03081-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3081"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03081-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"17 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marla Dubinsky reports being a consultant for AbbVie, Arena, Astra Zeneca, BMS, Boehringer Ingelheim, Eli Lilly and Company, Genentech, Janssen, Johnson and Johnson Innovative Medicine, Merck, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Sphyre, and Takeda. Aisha Vadhariya, Sylvia Su, and Frederick Durand are employees and shareholders of Eli Lilly and Company. Xian Zhou is an employee of Syneos Health, which received funding from Eli Lilly and Company in connection with this study. Claudine Clucas, Larissa Stassek, and Ariane K. Kawata are employees of Evidera, which received funding from Eli Lilly and Company in connection with this study. Simon Travis has received grants from AbbVie, BUHLMANN Diagnostics, ECCO, Eli Lilly and Company, Ferring Pharmaceuticals, International Organization for the Study of Inflammatory Bowel Disease, Janssen, Merck Sharp & Dohme, Norman Collison Foundation, Pfizer, Procter & Gamble, Schering-Plough, Takeda, UCB Pharma, Vifor Pharma, and Warner Chilcott; and reports other disclosures from Abacus Pharma, AbbVie, Actial Farmaceutica, ai4gi, Alcimed, Allergan, Amgen, Aptel, Arena Pharmaceuticals, Asahi Kasei Pharma, Aspen Pharmacare, Astellas, AstraZeneca, Atlantic Pharmaceuticals, Barco, Biocare Medical, Biogen, BL Pharma, Boehringer Ingelheim, Bristol Myers Squibb, BUHLMANN Diagnostics, Calcico Therapeutics, Celgene, Cellerix, Cerimon Pharmaceuticals, ChemoCentryx, Chiesi, Cisbio, Comcast, Coronado Biosciences, Cosmo Pharmaceuticals, Dr. Falk Pharma, Ducentis BioTherapeutics, Dynavax Technologies, Elan Pharma, Eli Lilly and Company, Enterome, Equillium, Ferring Pharmaceuticals, Galapagos NV, Genentech\/Roche, Genzyme, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Gr\u00fcnenthal, GW Pharmaceuticals, Immunocore, Indigo Biosciences, Janssen, Lexicon Pharmaceuticals, Medarex, MedTrix, Merck, Merrimack Pharmaceuticals, Mestag Therapeutics, Millennium Pharmaceuticals, Neovacs, Novartis, Novo Nordisk, NPS Pharmaceuticals\/Nycomed, Ocera Therapeutics, OPTIMA Pharma, Origin Pharma, Otsuka, Palau Pharma, Pentax Medical, Pfizer, PharmaVentures, Phesi, Phillips Pharma Group, Procter & Gamble, Pronota, Proximagen, Resolute Pharma, Robarts Clinical Trials, Sandoz, Santarus, Satisfai Health, Sensyne Health, Shire, Sigmoid Pharma, Sorriso Pharmaceuticals, Souffinez, SynDermix, Synthon, Takeda, Theravance Biopharma, TiGenix, Tillotts Pharma AG, Topivert, Trino Therapeutics with Wellcome Trust, TxCell SA, UCB Pharma, Vertex Pharma, VHsquared, Vifor Pharma, Warner Chilcott, and Zeria Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was compliant with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical guidelines and the International Conference on Harmonization guidelines on Good Clinical Practice. Informed consent forms and protocols received ethical review board approval before study initiation. Participants provided written informed consent before any procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}